OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

1.470 +0.130 (+9.70%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about OKYO Pharma Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket ↗

March 01, 2023

Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

March 01, 2023

It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!

Via InvestorPlace

OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease

February 28, 2023

From OKYO Pharma LTD

Via GlobeNewswire

Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution

February 23, 2023

By David Willey, Benzinga

Via TheNewswire.com

Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution

February 23, 2023

Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution

Via News Direct

Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough ↗

February 23, 2023

An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and...

Via Benzinga

OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory Board

February 23, 2023

World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma

From OKYO Pharma LTD

Via GlobeNewswire

Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 21, 2023

Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 21, 2023

Via Benzinga

Nasdaq Drops Over 100 Points; Walmart Issues Cautious Forecast ↗

February 21, 2023

U.S. stocks traded lower this morning, with the Nasdaq Composite dropping more than 100 points on Tuesday. Following the market opening Tuesday, The Dow traded down 1.15% to 33,438.86 while the NASDAQ...

Via Benzinga

BABA Stock Alert: What to Know as Ant Group Teams Up With China’s NBA League ↗

February 21, 2023

Alibaba (BABA) stock is a hot topic on Tuesday as investors react to news of Ant Group teaming up with China's NBA league.

Via InvestorPlace

Why Is OKYO Pharma (OKYO) Stock Down 19% Today? ↗

February 21, 2023

OKYO Pharma (OKYO) stock is falling on Tuesday following a recent rally as the company prepares for a presentation this week.

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 21, 2023

Via Benzinga

Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket ↗

February 21, 2023

Gainers Troika Media Group Inc (NASDAQ: TRKA) shares rose 65.9% to $0.37 in pre-market trading after dropping 4% on Friday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

February 21, 2023

It's time to start another day of trading with a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday!

Via InvestorPlace

OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.

February 21, 2023

From OKYO Pharma LTD

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

February 20, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

February 20, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 17, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 17, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 31, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

January 30, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 17, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

January 16, 2023

Via Benzinga

OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022

December 30, 2022

From OKYO Pharma LTD

Via GlobeNewswire

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

December 22, 2022

From OKYO Pharma LTD

Via GlobeNewswire

OKYO to Participate at Biotech Showcase

December 21, 2022

From OKYO Pharma LTD

Via GlobeNewswire

OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC

December 06, 2022

From OKYO Pharma LTD

Via GlobeNewswire

OKYO Pharma Limited - Change of Auditor

December 01, 2022

From OKYO Pharma LTD

Via GlobeNewswire

OKYO Pharma Limited – PDMR dealing

November 24, 2022

From OKYO Pharma LTD

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.